Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes

Donghoon Choi, Soo Kyung Kim, Sung Hee Choi, Young Guk Ko, Chul Woo Ahn, Yangsoo Jang, Sung Kil Lim, Hyun Chul Lee, Bong Soo Cha

Research output: Contribution to journalArticle

241 Citations (Scopus)

Abstract

OBJECTIVE - Despite the popularity of coronary stenting in coronary artery disease (CAD), restenosis remains a challenging clinical problem. This study evaluated the efficacy of rosiglitazone for preventing in-stent restenosis in type 2 diabetic patients. RESEARCH DESIGN AND METHODS - We conducted a prospective, randomized, case-controlled trial involving 95 diabetic patients with CAD who were randomly assigned to either the control or rosiglitazone group (48 and 47 patients, respectively). Quantitative coronary angiography (QCA) was performed at study entry and again at 6-month follow-up. The primary end point was the restenosis rate, which was determined by QCA. RESULTS - Eighty-three patients (45 patients with 55 lesions in the control group and 38 patients with 51 lesions in the rosiglitazone group) completed follow-up angiography. Rosiglitazone treatment for 6 months reduced fasting insulin concentration. The high-sensitivity C-reactive protein concentration was significantly reduced in the rosiglitazone group compared with that in the control group (from 2.92 ± 1.98 to 0.62 ± 0.44 mg/l, P < 0.001 vs. from 2.01 ± 1.33 to 1.79 ± 1.22 mg/l, P = NS). However, the baseline and follow-up glucose and lipid concentrations were not different between two groups. The rate of in-stent restenosis was significantly reduced in the rosiglitazone group compared with the control group (for stent lesions: 17.6 vs. 38.2%, P = 0.030). The rosiglitazone group had a significantly lower degree of diameter stenosis (23.0 ± 23.4% vs. 40.9 ± 31.9%, P = 0.004) compared with the control group. CONCLUSIONS - We demonstrated that treatment with rosiglitazone significantly reduces in-stent restenosis in diabetic patients with CAD who underwent coronary stent implantation.

Original languageEnglish
Pages (from-to)2654-2660
Number of pages7
JournalDiabetes Care
Volume27
Issue number11
DOIs
Publication statusPublished - 2004 Nov 1

Fingerprint

rosiglitazone
Coronary Restenosis
Type 2 Diabetes Mellitus
Stents
Coronary Artery Disease
Control Groups
Coronary Angiography
C-Reactive Protein

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Advanced and Specialised Nursing

Cite this

Choi, Donghoon ; Kim, Soo Kyung ; Choi, Sung Hee ; Ko, Young Guk ; Ahn, Chul Woo ; Jang, Yangsoo ; Lim, Sung Kil ; Lee, Hyun Chul ; Cha, Bong Soo. / Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes. In: Diabetes Care. 2004 ; Vol. 27, No. 11. pp. 2654-2660.
@article{403e7d9591f340969bfb4902db3ddc22,
title = "Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes",
abstract = "OBJECTIVE - Despite the popularity of coronary stenting in coronary artery disease (CAD), restenosis remains a challenging clinical problem. This study evaluated the efficacy of rosiglitazone for preventing in-stent restenosis in type 2 diabetic patients. RESEARCH DESIGN AND METHODS - We conducted a prospective, randomized, case-controlled trial involving 95 diabetic patients with CAD who were randomly assigned to either the control or rosiglitazone group (48 and 47 patients, respectively). Quantitative coronary angiography (QCA) was performed at study entry and again at 6-month follow-up. The primary end point was the restenosis rate, which was determined by QCA. RESULTS - Eighty-three patients (45 patients with 55 lesions in the control group and 38 patients with 51 lesions in the rosiglitazone group) completed follow-up angiography. Rosiglitazone treatment for 6 months reduced fasting insulin concentration. The high-sensitivity C-reactive protein concentration was significantly reduced in the rosiglitazone group compared with that in the control group (from 2.92 ± 1.98 to 0.62 ± 0.44 mg/l, P < 0.001 vs. from 2.01 ± 1.33 to 1.79 ± 1.22 mg/l, P = NS). However, the baseline and follow-up glucose and lipid concentrations were not different between two groups. The rate of in-stent restenosis was significantly reduced in the rosiglitazone group compared with the control group (for stent lesions: 17.6 vs. 38.2{\%}, P = 0.030). The rosiglitazone group had a significantly lower degree of diameter stenosis (23.0 ± 23.4{\%} vs. 40.9 ± 31.9{\%}, P = 0.004) compared with the control group. CONCLUSIONS - We demonstrated that treatment with rosiglitazone significantly reduces in-stent restenosis in diabetic patients with CAD who underwent coronary stent implantation.",
author = "Donghoon Choi and Kim, {Soo Kyung} and Choi, {Sung Hee} and Ko, {Young Guk} and Ahn, {Chul Woo} and Yangsoo Jang and Lim, {Sung Kil} and Lee, {Hyun Chul} and Cha, {Bong Soo}",
year = "2004",
month = "11",
day = "1",
doi = "10.2337/diacare.27.11.2654",
language = "English",
volume = "27",
pages = "2654--2660",
journal = "Diabetes Care",
issn = "1935-5548",
publisher = "American Diabetes Association Inc.",
number = "11",

}

Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes. / Choi, Donghoon; Kim, Soo Kyung; Choi, Sung Hee; Ko, Young Guk; Ahn, Chul Woo; Jang, Yangsoo; Lim, Sung Kil; Lee, Hyun Chul; Cha, Bong Soo.

In: Diabetes Care, Vol. 27, No. 11, 01.11.2004, p. 2654-2660.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes

AU - Choi, Donghoon

AU - Kim, Soo Kyung

AU - Choi, Sung Hee

AU - Ko, Young Guk

AU - Ahn, Chul Woo

AU - Jang, Yangsoo

AU - Lim, Sung Kil

AU - Lee, Hyun Chul

AU - Cha, Bong Soo

PY - 2004/11/1

Y1 - 2004/11/1

N2 - OBJECTIVE - Despite the popularity of coronary stenting in coronary artery disease (CAD), restenosis remains a challenging clinical problem. This study evaluated the efficacy of rosiglitazone for preventing in-stent restenosis in type 2 diabetic patients. RESEARCH DESIGN AND METHODS - We conducted a prospective, randomized, case-controlled trial involving 95 diabetic patients with CAD who were randomly assigned to either the control or rosiglitazone group (48 and 47 patients, respectively). Quantitative coronary angiography (QCA) was performed at study entry and again at 6-month follow-up. The primary end point was the restenosis rate, which was determined by QCA. RESULTS - Eighty-three patients (45 patients with 55 lesions in the control group and 38 patients with 51 lesions in the rosiglitazone group) completed follow-up angiography. Rosiglitazone treatment for 6 months reduced fasting insulin concentration. The high-sensitivity C-reactive protein concentration was significantly reduced in the rosiglitazone group compared with that in the control group (from 2.92 ± 1.98 to 0.62 ± 0.44 mg/l, P < 0.001 vs. from 2.01 ± 1.33 to 1.79 ± 1.22 mg/l, P = NS). However, the baseline and follow-up glucose and lipid concentrations were not different between two groups. The rate of in-stent restenosis was significantly reduced in the rosiglitazone group compared with the control group (for stent lesions: 17.6 vs. 38.2%, P = 0.030). The rosiglitazone group had a significantly lower degree of diameter stenosis (23.0 ± 23.4% vs. 40.9 ± 31.9%, P = 0.004) compared with the control group. CONCLUSIONS - We demonstrated that treatment with rosiglitazone significantly reduces in-stent restenosis in diabetic patients with CAD who underwent coronary stent implantation.

AB - OBJECTIVE - Despite the popularity of coronary stenting in coronary artery disease (CAD), restenosis remains a challenging clinical problem. This study evaluated the efficacy of rosiglitazone for preventing in-stent restenosis in type 2 diabetic patients. RESEARCH DESIGN AND METHODS - We conducted a prospective, randomized, case-controlled trial involving 95 diabetic patients with CAD who were randomly assigned to either the control or rosiglitazone group (48 and 47 patients, respectively). Quantitative coronary angiography (QCA) was performed at study entry and again at 6-month follow-up. The primary end point was the restenosis rate, which was determined by QCA. RESULTS - Eighty-three patients (45 patients with 55 lesions in the control group and 38 patients with 51 lesions in the rosiglitazone group) completed follow-up angiography. Rosiglitazone treatment for 6 months reduced fasting insulin concentration. The high-sensitivity C-reactive protein concentration was significantly reduced in the rosiglitazone group compared with that in the control group (from 2.92 ± 1.98 to 0.62 ± 0.44 mg/l, P < 0.001 vs. from 2.01 ± 1.33 to 1.79 ± 1.22 mg/l, P = NS). However, the baseline and follow-up glucose and lipid concentrations were not different between two groups. The rate of in-stent restenosis was significantly reduced in the rosiglitazone group compared with the control group (for stent lesions: 17.6 vs. 38.2%, P = 0.030). The rosiglitazone group had a significantly lower degree of diameter stenosis (23.0 ± 23.4% vs. 40.9 ± 31.9%, P = 0.004) compared with the control group. CONCLUSIONS - We demonstrated that treatment with rosiglitazone significantly reduces in-stent restenosis in diabetic patients with CAD who underwent coronary stent implantation.

UR - http://www.scopus.com/inward/record.url?scp=7444231513&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=7444231513&partnerID=8YFLogxK

U2 - 10.2337/diacare.27.11.2654

DO - 10.2337/diacare.27.11.2654

M3 - Article

C2 - 15505001

AN - SCOPUS:7444231513

VL - 27

SP - 2654

EP - 2660

JO - Diabetes Care

JF - Diabetes Care

SN - 1935-5548

IS - 11

ER -